Scholarly Index
Luis Jódar
Pfizer (United States); 8,673 total citations; 175 total publications; best world rank #118
Pfizer (United States)
8,673Total citations
175Total publications
42H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| SARS-CoV-2 and COVID-19 Research | Lifetime | 969 | US 327 | 97.08 |
| Pneumonia and Respiratory Infections | Lifetime | 852 | US 328 | 97.35 |
| Vaccine Coverage and Hesitancy | Lifetime | 746 | US 342 | 95.80 |
| Bacterial Infections and Vaccines | Lifetime | 945 | US 344 | 94.18 |
| SARS-CoV-2 and COVID-19 Research | 2021-2025 | 491 | US 161 | 97.99 |
| Pneumonia and Respiratory Infections | 2021-2025 | 118 | US 31 | 96.78 |
| Vaccine Coverage and Hesitancy | 2021-2025 | 220 | US 69 | 96.56 |
| Respiratory viral infections research | 2021-2025 | 301 | US 120 | 94.94 |
| Pneumocystis jirovecii pneumonia detection and treatment | 2021-2025 | 144 | US 33 | 92.78 |
| Viral Infections and Vectors | 2021-2025 | 602 | US 156 | 91.98 |
| Vector-borne infectious diseases | 2021-2025 | 291 | US 76 | 91.74 |
| Bacterial Infections and Vaccines | 2021-2025 | 369 | US 85 | 83.67 |